Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 3/20 | 0.62 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20786908 | 0.88 | ITGB3 (0.51) | PSMB1PSMB5ITGB3ITGA2BKMT2A | |
| SCHEMBL22390653 | 0.82 | KMO (0.51) | PSMB1PSMB5ITGB3ITGA2BKMT2A | |
| SCHEMBL18955878 | 0.81 | PSMB1 (0.58) | PSMB1PSMB5KMT2AKDM4EMCL1 | |
| SCHEMBL1919918 | 0.80 | PSMB1 (0.53) | PSMB1PSMB5KMT2AKDM4EPOLB | |
| SCHEMBL31241139 | 0.80 | PSMB1 (0.55) | PSMB1PSMB5KDM4EPOLB | |
| SCHEMBL26683806 | 0.80 | KMT2A (0.60) | KMT2AEGFRNTSR1 | |
| SCHEMBL31241086 | 0.78 | PSMB1 (0.48) | PSMB1PSMB5KMT2A | |
| SCHEMBL13392342 | 0.78 | PSMB1 (0.48) | PSMB1PSMB5KMT2A | |
| SCHEMBL10203523 | 0.78 | KMT2A (0.62) | PSMB1PSMB5KMT2AKDM4EPOLB | |
| SCHEMBL3519270 | 0.77 | PSMB5 (0.50) | PSMB1PSMB5KMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| EP-3386591-B1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | CADENT THERAPEUTICS INC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180362541-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-20 | — | — | US | disclosed |
| EP-3386591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | Cadent Therapeutics, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017100591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | PSMB1 3118/4885PSMB5 2398/4885ITGB3 4168/4885 |
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | PSMB1 3118/4885PSMB5 2398/4885ITGB3 4168/4885 |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | PSMB1 3118/4885PSMB5 2398/4885ITGB3 4168/4885 |
| US-20180362541-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | PSMB1 3118/4885PSMB5 2398/4885ITGB3 4168/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | PSMB1 3118/4885PSMB5 2398/4885ITGB3 4168/4885 |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | PSMB1 3118/4885PSMB5 2398/4885ITGB3 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.